Effects of quinidine versus procainamide on the QT interval

The American Journal of Cardiology
M J ReiterD E Mann

Abstract

Eighteen patients were given quinidine and procainamide separately to evaluate whether prolongation of the QT interval by type Ia antiarrhythmic agents is a drug-specific phenomenon. Doses were titrated to achieve standard trough therapeutic levels of quinidine (2 to 5 micrograms/ml) and procainamide (4 to 12 micrograms/ml). In 16 of the 18 patients, the increase in corrected QT interval (QTc) was greater with quinidine than with procainamide, averaging 78 +/- 10 ms (+/- standard error of the mean) with quinidine and 39 +/- 7 ms with procainamide (p less than 0.001). The greater degree of QTc prolongation with quinidine than with procainamide was not due to differences in sinus cycle length, QRS duration, serum potassium level or concomitant drug therapy. Differences in relative drug level did not appear to account for the greater effect of quinidine. Thus, at frequently used plasma levels, quinidine prolongs QTc to a greater degree than does procainamide. This effect does not appear to be due to the comparison of "nonequivalent" drug levels.

References

Feb 1, 1976·The American Journal of Cardiology·N O FowlerI B Hanenson
Feb 1, 1977·Journal of Clinical Pharmacology·A FieldmanM Sing Sum Chow
Sep 1, 1977·Circulation·J A KastorL N Horowitz
Oct 1, 1977·British Heart Journal·G I FiddlerM J Godman
Apr 1, 1985·The Tohoku Journal of Experimental Medicine·E OdaA Shibata
Mar 1, 1971·JAMA : the Journal of the American Medical Association·J Koch-Weser, S W Klein
Nov 1, 1983·Journal of the American College of Cardiology·G N KayA L Waldo
Jan 1, 1983·The American Journal of Cardiology·J P DiMarcoJ N Ruskin
Jul 1, 1983·The American Journal of Cardiology·K F BrowneD P Zipes
Oct 1, 1980·Annals of Internal Medicine·W M Smith, J J Gallagher
Mar 1, 1982·Clinical Pharmacokinetics·J E Brown, D G Shand
Jun 1, 1982·The American Journal of Cardiology·J SofferE L Michelson
Nov 1, 1982·The American Journal of Cardiology·K F BrowneE N Prystowsky
Mar 20, 1965·Lancet·C ROMANO
Sep 1, 1952·Circulation·E LEPESCHKIN, B SURAWICZ

❮ Previous
Next ❯

Citations

Jan 1, 1991·Integrative Physiological and Behavioral Science : the Official Journal of the Pavlovian Society·M H HuangS Wolf
Oct 1, 1988·British Journal of Clinical Pharmacology·R A Wooding-ScottR L Slaughter
Jun 15, 2014·European Journal of Pharmacology·Constanze SchmidtDierk Thomas
Jul 17, 2018·Naunyn-Schmiedeberg's Archives of Pharmacology·Ingo StaudacherDierk Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.